<DOC>
	<DOCNO>NCT03052322</DOCNO>
	<brief_summary>The purpose study compare efficacy , safety immunogenicity MSB11022 HumiraÂ® adult subject rheumatoid arthritis .</brief_summary>
	<brief_title>MSB11022 Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis base 2010 ACR/EULAR criterion At least 6 tender ( 68 assess ) 6 swollen ( 66 assess ) joint screen baseline Must receive methotrexate least 12 week stable dose least 4 week prior first study dose Evidence untreated inadequately treated latent active Tuberculosis Evidence uncontrolled , clinically significant disease Any second diseasemodifying antirheumatic drug must wash prior first study dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>